Trial Profile
Clinical value of blood neutrophil-to-lymphocyte ratio factor in patients with unresectable/metastatic gastrointestinal stromal tumors treated with sunitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2018
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Pharmacodynamics; Therapeutic Use
- 28 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology